Pierre Socha

With the power to skillfully write meaningful DNA sequences, we embark on a new era where precise control over biology and the manipulation of matter in our environment is possible. Constructive Biology is a spin out from the laboratory of Prof. Jason Chin at the MRC Laboratory of Molecular Biology in Cambridge. Our platform allow us to fundamentally reprogram the genetic code, and make molecules that nature could not make before. We will use our technologies to biosynthesize new classes of enzymes, pharmaceuticals and biomaterials. If you would like to join our team, get in touch!

At Quibim, we design pioneering tools that unlock imaging data to improve patient outcomes. Our main purpose is the application of AI techniques to medical images from MRI, CT, PET to unlock new data which can be transformed into actionable predictions for life sciences and providers.

CS Genetics is developing groundbreaking new technology for single-cell genomics, based on foundational scientific insights and sophisticated innovations. We've developed a disruptive platform for single-cell genomics which leverages instrument-free, solution-phase chemical biology to provide unmatched ease-of-use, scalability, and affordability.

V7s flagship platforms, V7 Darwin, and V7 Go, allow you to turn your data into trustworthy AI models, and GenAI-fuelled automation workflows. V7 Darwin offers a complete toolkit for your training data engine: Automated labeling tools, models in the loop, annotation services, and a powerful API. V7 Go uses best-in-class foundation models from OpenAI, Gemini, and Anthropic, to allow you to automate multi-modal tasks, reliably at scale. Teach AI, and put it to work, with our platforms now: https://www.v7labs.com/

Over 10 million people around the world are suffering with stiffness and slowness caused by Parkinson’s Disease. CUE1, a focused vibrotactile stimulation device, has granted all of the pilot participants improved movement. Participants claimed that they felt their movement was smoother and better coordinated when using the device.

Ori Biotech is a London- and Philadelphia-based leader in CGT manufacturing technology that has developed a proprietary, bespoke and flexible manufacturing platform, which enables patient access to a new generation of personalized, lifesaving treatments. By fully automating and standardizing CGT manufacturing in a closed platform, Ori offers therapeutics developers the opportunity to seamlessly scale from pre-clinical process development to commercial scale manufacturing. So complex manufacturing challenges can be put where they belong – in the past.

AI VIVO is a Cambridge (UK) based company with a unique systems pharmacology platform powered by AI to accelerate drug discovery. We believe biology, health and disease are all about balance and imbalance. Our platform provide a proprietary system-driven methodology to represent these imbalances using functional omics data and predict unexpected novel modulation strategies to restore the stability and alleviating pathological imbalance. This disruptive technology enables us to speed up the whole drug discovery process by identify promising candidates, de-risk the opportunities through preclinical validations, and progress drug candidates to the clinic through industry and investor partnerships.

Ori Biotech is a London- and Philadelphia-based leader in CGT manufacturing technology that has developed a proprietary, bespoke and flexible manufacturing platform, which enables patient access to a new generation of personalized, lifesaving treatments. By fully automating and standardizing CGT manufacturing in a closed platform, Ori offers therapeutics developers the opportunity to seamlessly scale from pre-clinical process development to commercial scale manufacturing. So complex manufacturing challenges can be put where they belong – in the past.

Lightcast is developing a novel, droplet-based platform that provides a deeper understanding of cellular function. Compared to standard microfluidic methods, the Lightcast platform offers the ability to run a broader range of assays and to precisely control and track the number, occupancy, location, and movement of each droplet. The unprecedented scalability and flexibility of this approach will help advance translational and basic research as well as streamline development workflows for drugs, therapeutics, and applied biologics.

At Biofidelity, we’re working toward a future where more people around the world have access to the life-changing power of genomics. Our novel molecular technologies simplify genomic analysis, so more patients have access to the information needed to ensure the best possible outcomes. Our vision doesn’t end with oncology, though. Our revolutionary technologies will pave the way for tomorrow’s yet-unknown scientific breakthroughs. We believe in the transformational power of genomics. We believe that with imagination and ingenuity, anything is possible. Most importantly, when it comes to humanity’s most complex problems, we believe in the power of simple.

Synthace is a digital experiment platform built for high-performance life science R&D teams to help them run more powerful experiments and accelerate scientific progress. It allows biologists to design, plan, and automate experiments in a single place, then automatically gather structured experiment data and metadata in a unified no-code environment.

Secondmind exists to help automotive engineers design better cars faster. The company’s cloud-native software, powered by Secondmind Active Learning, addresses the increasing complexity of vehicle design and development by reducing design simulation time and calibration overhead, enabling engineers to reimagine vehicle design and accelerate the transition to carbon-neutral mobility. Founded in 2016 and supported by investors such as Amadeus Capital, Atlantic Bridge, Cambridge Innovation Capital and Mazda, Secondmind was recently recognized with the Automotive Testing Technology International Alternative Powertrain Test Innovation of the Year Award; selected for the Tech Nation Future Fifty scale-up program, and named by Bloomberg as one of the UK’s 25 startups to watch. Secondmind® Secondmind® is a registered trademark of Secondmind Ltd.

Five is building self-driving software components and development platforms to help autonomy programs solve the industry’s greatest challenges. In doing so, we will help turn today’s promising engineering systems into tomorrow’s trusted mobility solutions and improve the lives of millions of people, in countless ways. We’ve learnt a lot from successfully building our own high-functioning, complete self-driving system and testing it on London’s public roads. We now define our mission in two ways: 1. Deliver advanced online components that address the most under-solved challenges in self-driving systems. 2. Build a modular, cloud-based platform that delivers performance and scale for system development and assurance. To make this a reality, we’re looking for creative problem-solvers and practical doers from a range of backgrounds in areas such as software engineering, robotics, machine learning, computer vision, AI, mathematics, control engineering, software assurance, simulation, verification and motor sport. We welcome people from all backgrounds, at all levels. If you’re talented, ambitious, and want to build the future with an incredibly smart, friendly, creative and inclusive team, we’d love to hear from you. To see all our current vacancies, visit: https://careers.five.ai/

Doctify is a high-growth HealthTech company revolutionising the global healthcare market. Having expanded into 6 markets with an ambitious growth plan over the coming year. Doctify has developed a first-of-its-kind healthcare-specific patient feedback and review product allowing healthcare professionals to drive improvements in patient care on a daily basis. Our SaaS product allows healthcare providers to collect and digitize patient feedback and publish it through multiple channels (both externally and internally). Underpinning it is a SaaS platform that provides insights and analytics into the care they provide. It means for the first time patients can read real-time verified feedback for a hospital, clinic, or doctor for a specific condition or procedure.  The company was founded by two orthopaedic surgeons in 2015 with the goal of providing more trust and transparency in healthcare. It quickly grew from an idea to a revenue-generating business in less than a year and continues to thrive. Backed by industry-leading European funds Amadeus capital, Keen ventures as well as backers such Sir John Hegarty (the founder of Saatchi and Saatchi) and Tom Teichmann (backer of Lastminute.com, Not on the highstreet, Made.com, Simba Sleep).  Since then we have added over 25,000 doctors, hospitals, and clinics across 4 international markets, doubled our team across 6 countries and have won numerous awards along the way in recognition of our commitment to bringing greater levels of trust and transparency to the doctor-patient relationship. Most recently recognised as the 2021 Vitality Supplier of the Year.

Healx is a mission-driven technology company pioneering the next generation of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. There are more than 10,000 known rare diseases that affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. By combining frontier AI technology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development in order to meet this huge unmet need and have unprecedented patient impact.

With the power to skillfully write meaningful DNA sequences, we embark on a new era where precise control over biology and the manipulation of matter in our environment is possible. Constructive Biology is a spin out from the laboratory of Prof. Jason Chin at the MRC Laboratory of Molecular Biology in Cambridge. Our platform allow us to fundamentally reprogram the genetic code, and make molecules that nature could not make before. We will use our technologies to biosynthesize new classes of enzymes, pharmaceuticals and biomaterials. If you would like to join our team, get in touch!

At Quibim, we design pioneering tools that unlock imaging data to improve patient outcomes. Our main purpose is the application of AI techniques to medical images from MRI, CT, PET to unlock new data which can be transformed into actionable predictions for life sciences and providers.

CS Genetics is developing groundbreaking new technology for single-cell genomics, based on foundational scientific insights and sophisticated innovations. We've developed a disruptive platform for single-cell genomics which leverages instrument-free, solution-phase chemical biology to provide unmatched ease-of-use, scalability, and affordability.

V7s flagship platforms, V7 Darwin, and V7 Go, allow you to turn your data into trustworthy AI models, and GenAI-fuelled automation workflows. V7 Darwin offers a complete toolkit for your training data engine: Automated labeling tools, models in the loop, annotation services, and a powerful API. V7 Go uses best-in-class foundation models from OpenAI, Gemini, and Anthropic, to allow you to automate multi-modal tasks, reliably at scale. Teach AI, and put it to work, with our platforms now: https://www.v7labs.com/

Over 10 million people around the world are suffering with stiffness and slowness caused by Parkinson’s Disease. CUE1, a focused vibrotactile stimulation device, has granted all of the pilot participants improved movement. Participants claimed that they felt their movement was smoother and better coordinated when using the device.